4P7E

Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 
    0.267 (Depositor), 0.270 (DCC) 
  • R-Value Work: 
    0.205 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 
    0.208 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 2HBClick on this verticalbar to view details

This is version 2.2 of the entry. See complete history


Literature

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.

Menet, C.J.Fletcher, S.R.Van Lommen, G.Geney, R.Blanc, J.Smits, K.Jouannigot, N.Deprez, P.van der Aar, E.M.Clement-Lacroix, P.Lepescheux, L.Galien, R.Vayssiere, B.Nelles, L.Christophe, T.Brys, R.Uhring, M.Ciesielski, F.Van Rompaey, L.

(2014) J Med Chem 57: 9323-9342

  • DOI: https://doi.org/10.1021/jm501262q
  • Primary Citation of Related Structures:  
    4P7E

  • PubMed Abstract: 

    Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).


  • Organizational Affiliation

    Galapagos NV , Generaal de Wittelaan L11A3, 2800 Mechelen, Belgium.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein kinase JAK2
A, B
293Homo sapiensMutation(s): 1 
Gene Names: JAK2
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for O60674 (Homo sapiens)
Explore O60674 
Go to UniProtKB:  O60674
PHAROS:  O60674
GTEx:  ENSG00000096968 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO60674
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
2HB
Query on 2HB

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
C21 H23 N5 O3 S
RIJLVEAXPNLDTC-UHFFFAOYSA-N
Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
PTR
Query on PTR
A, B
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
Binding Affinity Annotations 
IDSourceBinding Affinity
2HB BindingDB:  4P7E IC50: min: 25, max: 1.75e+4 (nM) from 24 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free:  0.267 (Depositor), 0.270 (DCC) 
  • R-Value Work:  0.205 (Depositor), 0.200 (DCC) 
  • R-Value Observed: 0.208 (Depositor) 
Space Group: P 41
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 111.39α = 90
b = 111.39β = 90
c = 71.08γ = 90
Software Package:
Software NamePurpose
iMOSFLMdata reduction
SCALAdata scaling
PDB_EXTRACTdata extraction
PHASERphasing
REFMACrefinement
MOSFLMdata reduction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 2HBClick on this verticalbar to view details

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2014-11-19
    Type: Initial release
  • Version 1.1: 2014-12-10
    Changes: Database references
  • Version 2.0: 2019-08-21
    Changes: Atomic model, Data collection, Derived calculations
  • Version 2.1: 2023-12-20
    Changes: Data collection, Database references, Refinement description
  • Version 2.2: 2024-10-09
    Changes: Structure summary